Teligent Inc. (NASDAQ:TLGT) fell 3.5% on Wednesday . The stock traded as low as $7.97 and last traded at $8.02, with a volume of 88,926 shares traded. The stock had previously closed at $8.31.

Several brokerages have recently weighed in on TLGT. Zacks Investment Research downgraded Teligent from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 30th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Teligent in a report on Tuesday, April 26th. TheStreet raised Teligent from a “sell” rating to a “hold” rating in a report on Thursday, June 23rd. JMP Securities began coverage on Teligent in a report on Wednesday, June 29th. They issued a “hold” rating for the company. Finally, Raymond James Financial Inc. began coverage on Teligent in a report on Wednesday, June 22nd. They issued a “strong-buy” rating and a $11.00 price target for the company. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $9.42.

The stock’s market cap is $421.04 million. The stock’s 50 day moving average is $8.11 and its 200 day moving average is $6.36.

Teligent (NASDAQ:TLGT) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.04. The firm had revenue of $17.14 million for the quarter, compared to analysts’ expectations of $16.03 million. During the same quarter in the prior year, the business posted ($0.05) earnings per share. Teligent’s revenue was up 92.8% on a year-over-year basis. On average, equities analysts expect that Teligent Inc. will post $0.05 EPS for the current fiscal year.

Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.